Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Resolution Bioscience
Kirkland, Washington, United States
- Ownership
- Private
- Employees
- ~51
- Development stage
- Other
01
Overview
The ctDx platform, a next-generation sequencing (NGS) liquid biopsy assay, provided comprehensive genomic profiling and companion diagnostics in oncology. Published studies demonstrated its ability to deliver actionable genetic information for therapy selection, monitor resistance evolution, and guide clinical decision-making with high positive predictive value, including FDA Breakthrough Device Designation for its HRD assay[3][5].
- Therapeutic areas
- Oncology
- Modalities
- DeviceCompanion diagnostic platform
- Industry
- Molecular Diagnostics
02
Partnerships
LabCorpJanssen
Beyond the preview
Go deeper on Resolution Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Resolution Bioscience.